Literature DB >> 16314955

A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.

Murali M Chintagumpala1, Henry S Friedman, Clinton F Stewart, James Kepner, Roger E McLendon, Paul L Modrich, Charles McCluggage, Peter Burger, Emi Holmes, Stephen Thompson, James Rutka, Jeff Michalski, Shiao Woo, Susan M Blaney, Larry E Kun, Marc E Horowitz.   

Abstract

The role of chemotherapy in the treatment of high-grade gliomas in children is unclear. Early reports were suggestive of improved outcome in children with high-grade glioma with the addition of chemotherapy after surgery and radiation therapy. Subsequent studies did not show similar favorable contribution of chemotherapy to the outcome of these children. Further efforts to identify active chemotherapy agents in children include use of agents that have shown efficacy in adult patients with high-grade glioma and agents that have shown promise in mice bearing human xenografts of brain tumors. A Pediatric Oncology Group (POG 9431) trial tested the activity of two such agents, procarbazine and topotecan in newly diagnosed patients with high-grade glioma who had measurable disease after diagnostic surgery. Neither agent showed efficacy within the confines of the statistical design of the study. This study showed that children with high-grade glioma have an innate resistance to alkylating agents based on mismatch repair deficiency and high levels of alkyguanine transferase (AGT). Future trials should consider strategies to overcome the resistance mechanisms in children with high-grade glioma.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16314955     DOI： 10.1007/s11060-005-9024-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  24 in total

1.  Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas.

Authors:  R E McLendon; L Cleveland; C Pegram; S H Bigner; D D Bigner; H S Friedman
Journal:  Lab Invest       Date:  1998-05       Impact factor: 5.662

2.  Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.

Authors:  W C Zamboni; C F Stewart; J Thompson; V M Santana; P J Cheshire; L B Richmond; X Luo; C Poquette; J A Houghton; P J Houghton
Journal:  J Natl Cancer Inst       Date:  1998-04-01       Impact factor: 13.506

3.  Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.

Authors:  H S Friedman; P J Houghton; S C Schold; S Keir; D D Bigner
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.

Authors:  Clinton F Stewart; Lisa C Iacono; Murali Chintagumpala; Stewart J Kellie; David Ashley; W C Zamboni; M N Kirstein; Maryam Fouladi; Louis G Seele; Dana Wallace; Peter J Houghton; Amar Gajjar
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

5.  Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.

Authors:  H B Newton; J Bromberg; L Junck; M A Page; H S Greenberg
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

6.  Changes in O6-methylguanine-DNA methyltransferase expression during immortalization of cloned human fibroblasts.

Authors:  L C Harris; M A von Wronski; C C Venable; J S Remack; S R Howell; T P Brent
Journal:  Carcinogenesis       Date:  1996-02       Impact factor: 4.944

7.  Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development.

Authors:  M E Horowitz; E Etcubanas; M L Christensen; J A Houghton; S L George; A A Green; P J Houghton
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

8.  DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

Authors:  H S Friedman; R E McLendon; T Kerby; M Dugan; S H Bigner; A J Henry; D M Ashley; J Krischer; S Lovell; K Rasheed; F Marchev; A J Seman; I Cokgor; J Rich; E Stewart; O M Colvin; J M Provenzale; D D Bigner; M M Haglund; A H Friedman; P L Modrich
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

9.  O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.

Authors:  S C Schold; T P Brent; E von Hofe; H S Friedman; S Mitra; D D Bigner; J A Swenberg; P Kleihues
Journal:  J Neurosurg       Date:  1989-04       Impact factor: 5.115

10.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

Authors:  S B Green; D P Byar; M D Walker; D A Pistenmaa; E Alexander; U Batzdorf; W H Brooks; W E Hunt; J Mealey; G L Odom; P Paoletti; J Ransohoff; J T Robertson; R G Selker; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  Cancer Treat Rep       Date:  1983-02
View more
  6 in total

1.  Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.

Authors:  Jun Shen; Angel M Carcaboso; K Elaine Hubbard; Michael Tagen; Henry G Wynn; John C Panetta; Christopher M Waters; Mohamed A Elmeliegy; Clinton F Stewart
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

2.  Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.

Authors:  Angel M Carcaboso; Mohamed A Elmeliegy; Jun Shen; Stephen J Juel; Ziwei M Zhang; Christopher Calabrese; Lorraine Tracey; Christopher M Waters; Clinton F Stewart
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

Review 3.  Treatment of high-grade glioma in children and adolescents.

Authors:  T J MacDonald; D Aguilera; C M Kramm
Journal:  Neuro Oncol       Date:  2011-07-22       Impact factor: 12.300

4.  A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.

Authors:  Regina I Jakacki; Allan Yates; Susan M Blaney; Tianni Zhou; Robert Timmerman; Ashish M Ingle; Lynda Flom; Michael D Prados; Peter C Adamson; Ian F Pollack
Journal:  Neuro Oncol       Date:  2008-05-22       Impact factor: 12.300

5.  Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming.

Authors:  Joshua D Bernstock; Daniel Ye; Florian A Gessler; Yang-Ja Lee; Luca Peruzzotti-Jametti; Peter Baumgarten; Kory R Johnson; Dragan Maric; Wei Yang; Donat Kögel; Stefano Pluchino; John M Hallenbeck
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

6.  Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway.

Authors:  Mohammad Hassan Hodroj; Achraf Jardaly; Sarah Abi Raad; Annalise Zouein; Sandra Rizk
Journal:  Cancer Manag Res       Date:  2018-05-10       Impact factor: 3.989
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.